Trial Profile
A Randomized, Double-blind, Placebo Controlled, Multicenter Phase II Study to Assess the Efficacy and Safety of Sorafenib Added to Standard Treatment With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TRIAS
- 09 Aug 2018 Results published in the Lancet Oncology
- 07 Jun 2016 Primary endpoint (Progression-free survival rate) has been met, as per the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology